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Summary
Objectives: To determine the mortality rate and risk factors after experiencing symptomatic
hyperlactatemia in HIV-infected patients receiving antiretroviral therapy (ART).
Methods: A retrospective cohort study was conducted among patients who were diagnosed with
symptomatic hyperlactatemia (lactate >2.5 mmol/l) between January 2004 and April 2006. All
patients were followed until 3 months after the diagnosis.
Results: One hundred and twenty-five patients were included in the study. The mean  standard
deviation (SD) age was 39.9  10.1 years and body weight was 58.2  16.9 kg; 60.8% were male.
Symptomatic hyperlactatemia in 114 (91.2%) was associatedwith receiving d4T, in five (4.0%) with
d4T+ddI, in four (3.2%) with ZDV+ddI, and in two (1.6%) with ddI (d4T, stavudine; ddI, didanosine;
ZDV, zidovudine). The median duration of ARTwas 13 months. Nine (7.2%) patients died. Patients
who died had a higher mean lactate level (8.0 vs. 5.1 mmol/l) andmean alanine aminotransferase
(ALT; 164 vs. 48 U/l) at the time of diagnosis when compared to those who survived ( p < 0.05).
Patients who died had a lower mean weight than those who survived (48 vs. 59 kg, p = 0.008). By
logistic regression, mortality was associated with patients whose body weight was <45 kg§ The abstract of this study was presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago,
USA, September 17—20, 2007; H-375.
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(p = 0.014, odds ratio (OR) 9.090, 95% confidence interval (CI) 1.575—52.632) and whose serum
lactate was >10 mmol/l (p = 0.004, OR 20.372, 95% CI 2.610—159.001).
Conclusions: The mortality rate of symptomatic hyperlactatemia among HIV-infected patients
receiving ART is substantial. Almost all patients received d4T. Patients who have a low body weight
and high serum lactate level are at a higher risk of mortality.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Fatal lactic acidosis frommitochondrial dysfunction has been
described as a serious complication of antiretroviral therapy
(ART) with nucleoside analogues in HIV-infected patients.
The mechanism is that nucleoside reverse transcriptase inhi-
bitor (NRTI)-mediated inhibition of DNA polymerase gamma
leads to overproduction of lactate from anaerobic glycoly-
sis.1—3 However, HIV-infected patients with elevated serum
lactate levels may be asymptomatic, chronically ill, or
acutely severely ill.4,5 Hyperlactatemia without symptoms
or with mild symptoms is observed in the range of 8—20% of
HIV-infected patients receiving NRTI therapy for months or
for years.6,7 Most reports have demonstrated symptomatic
hyperlactatemia of 0.5—1/100 patient-years of NRTI expo-
sure.8—10 The clinical symptoms include fatigue, nausea,
vomiting, abdominal pain, weight loss, prostration, and dys-
pnea. Severe lactic acidosis is typically symptomatic with
rapid or precipitous progress to metabolic acidosis with
hyperventilation, arrhythmias, and multiple organ failure.4,5
To date, various risk factors of NRTI-associated lactic
acidosis have been recognized; these include long duration
of NRTI therapy, use of didanosine (ddI) combined with
stavudine (d4T), obesity, female gender, pregnancy, and
therapy with ribavirin or hydroxyl urea.11—16 Recently, ART
in resource-limited settings has been scaled up with the
public health approach, and d4T is primarily used in the
ART regimen. Data regarding clinical outcomes, mortality
rate, and risk factors of death among patients with sympto-
matic hyperlactatemia are still scarce, particularly in the
resource-limited setting. We therefore conducted the pre-
sent study to determine themortality rate after experiencing
symptomatic hyperlactatemia in HIV-infected patients
receiving ART. In addition, this study also aimed to determine
the clinical outcomes and risk factors related to mortality in
these patients.
Methods
A retrospective cohort study was conducted among HIV-
infected patients who were diagnosed with symptomatic
hyperlactatemia between January 2004 and April 2006 at
Bamrasnaradura Infectious Diseases Institute, Ministry of
Public Health, Nonthaburi, Thailand. This Institute is a ter-
tiary care and referral center for HIV-infected patients from
Nonthaburi Province and the northwestern part of Bangkok.
The patient identification numbers were identified from the
annual database of the institute. Data were extracted from
the medical records. Inclusion criteria were as follows: (1)
HIV-infected patients >15 years of age, (2) receiving anti-
retroviral therapy, (3) diagnosed with symptomatic hyper-lactatemia, and (4) with serum lactate greater than
2.5 mmol/l. The patients were excluded if: (1) they had
no definite date of ART initiation in their medical records,
such as transferred from another hospital or (2) the baseline
(prior to ART initiation) serum creatinine was>2.0 mg/dl. All
patients were followed until 3 months after the diagnosis of
symptomatic hyperlactatemia. Patients were categorized
into two groups based on their vital status: patients who
died and patients who survived.
The primary outcome of interest was the mortality rate of
symptomatic hyperlactatemia. Secondary objectives were to
determine the clinical outcomes and possible risk factors
related to mortality after the diagnosis of symptomatic
hyperlactatemia. Possible risk factors along with other data
collected were studied. These included patient demo-
graphics, baseline CD4 cell counts, baseline previous liver
enzymes, blood chemistry panel, and serum lactate levels at
the time of the diagnosis of symptomatic hyperlactatemia.
Routine blood samples for the measurement of lactate
were collected at rest (at least 15 min of rest occurred prior
to phlebotomy), without the use of tourniquets and without
fist clenching while the blood was drawn. The samples were
kept in fluoride tubes to prevent further lactate production
and were rapidly delivered to the test laboratory on ice;
testing was carried out using the COBAS INTEGRA 400.
Mean ( standard deviation, SD), median (interquartile
range, IQR), and frequencies (%) were used to describe
patient characteristics. The binary logistic regression model
was used to determine the risk of mortality after the diag-
nosis of symptomatic hyperlactatemia by adjusting for con-
founding factors, i.e., age, gender, body weight, duration of
ART, and lactate level. The odds ratio (OR) and its 95%
confidence interval (CI) were estimated. All analyses were
performed using SPSS version 11.5. A p-value less than 0.05
was considered statistically significant and presented as two
sides. The study was reviewed and approved by the institu-
tional review board and ethics committee of the Department
of Disease Control, Ministry of Public Health, Thailand.Results
A total of 125 patients met the inclusion criteria and their
medical records were retrieved and reviewed. The mean (
SD) age was 39.9  10.1 years; 60.8% were male. The mean
( SD) body weight was 58.2  16.9 kg. The most frequent
presenting symptoms included nausea and vomiting (42.4%),
progressive dyspnea (20.8%), lethargy (19.2%), abdominal
discomfort (19.2%), and motor weakness and/or sensory
impairment (10.4%). The related NRTIs used at the time of
the hyperlactatemic events were as follows: d4T (114
patients, 91.2%), d4T+ddI (five patients, 4.0%), zidovudine
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Table 1 Baseline characteristics of the study patients
Demographics Died (N = 9) Survived (N = 116) p-Value
Age, years (mean  SD) 38.8  7.8 40.0  10.2 0.718
Female gender (n (%)) 3 (33.3%) 46 (39.7%) 1.000
Weight, kg (mean  SD) 48.2  11.3 59.0  11.6 0.008
Duration of ART, days (mean  SD) 386.3  312.6 484.7  294.3 0.338
Baseline CD4 cell count, cells/mm3 (median (IQR)) 97 (54—258) 96 (166—275) 0.356
Baseline CD4 percentage, % (median (IQR)) 7 (5—18) 9 (5—13) 0.644
Baseline serum ALP, mg/dl (mean  SD) 146.5  47.7 166.9  231.8 0.863
Baseline serum ALT, U/l (mean  SD) 36.0  23.0 52.6  35.4 0.363
Serum creatinine, mg/dl (mean  SD) 1.7  1.4 0.8  0.4 0.007
Serum bicarbonate level, mmol/l (mean  SD) 13.0  7.1 21.3  4.3 <0.001
Anion gap, mmol/l (mean  SD) 24.1  10.6 18.8  3.8 0.029
Current ALP, mg/dl (mean  SD) 292.3  156.3 98.9  48.9 <0.001
Current ALT, U/l (mean  SD) 164.3  168.6 47.9  32.9 <0.001
Serum lactate level, mg/dl (mean  SD) 8.0  6.7 5.1  2.3 0.003
Serum lactate >10 mmol/l (mean  SD) 3 (33.3%) 4 (3.4%) 0.008
SD, standard deviation; ART, antiretroviral therapy; IQR, interquartile range; ALP, alkaline phosphatase; ALT, alanine aminotransferase.(ZDV)+ddI (four patients, 3.2%), and ddI (two patients, 1.6%).
The median (IQR) duration of ARTwas 13 (10—18) months and
median (IQR) CD4 cell count was 161 (94—275) cells/mm3.
During the 3-month follow-up period, nine (7.2%) patients
died; 116 (92.8%) patients survived. Mortality rates at 0.5, 1,
2, and 3 months after the diagnosis of symptomatic hyper-
lactatemia were 4.8%, 5.6%, 6.4%, and 7.2%, respectively. A
comparison of the patient characteristics between the two
groups is shown in Table 1. The patients who died had a lower
bodyweight, a lower serum bicarbonate level, a higher serum
alkaline phosphatase (ALP) level, a higher alanine amino-
transferase (ALT) level, and a higher proportion of patients
with lactate >10 mmol/l ( p < 0.05).
A binary logistic regression model showed that a high
lactate level and a low baseline body weight were associated
with a higher probability of death after the diagnosis of
symptomatic hyperlactatemia ( p < 0.05), as shown in
Table 2. The other possible risk factors in this model were
not associated with mortality.
The median (IQR) time from the diagnosis of symptomatic
hyperlactatemia to mortality was 10 (0—34) days. The mor-
tality rate was associated with the lactate level as follows:
2.5—4.9 mmol/l, 6.6% (5/76); 5—9.9 mmol/l, 2.4% (1/42);
10—14.9 mmol/l, 20.0% (1/5); and >15 mmol/l, 100% (2/2).
Three patients died within the first 24 hours after admission;
their lactate levels were 21.1, 11.7, and 4.1 mmol/l. Related
NRTI drugs were discontinued in all patients and fluid resus-
citation was given. None of the patients received hemodia-Table 2 Binary logistic regression of possible risk factors for dea
Risk factors p-Value
Lactate level >10 mmol/l 0.004
Body weight <45 kg 0.014
Duration of ART 0.458
Gender 0.632
Age 0.872
OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy.lysis. Causes of mortality in seven of nine patients were
directly related to severe symptomatic hyperlactatemia,
including respiratory failure and pancreatitis. The causes
of mortality in the remaining two patients were related to
secondary infections after the diagnosis of symptomatic
hyperlactatemia: bacterial pneumonitis with sepsis in one
patient and brain abscess with sepsis in the other.Discussion
The results from the present study demonstrate that the
overall mortality rate among HIV-infected patients who
experienced symptomatic hyperlactatemia was 7.2%. This
number is markedly high and should be considered of major
concern. Most of the patients presented with non-specific
symptoms. Thus, early diagnosis needs a high level of suspi-
cion for this condition. Early diagnosis can lead to immediate
cessation of the suspected NRTI, which is the most important
management.
To date, several studies have confirmed that hyperlacta-
temia and lactic acidosis are caused bymitochondrial toxicity
through the inhibition of mitochondrial DNA polymerase
gamma by various NRTIs.1—3 The mitochondrial toxicity also
results in hepatic steatosis, myopathy, and neuropathy.17,18
The frequency in rank order is d4T+ddI, d4T, ddI+ZDV. The
other NRTIs, such as abacavir and tenofovir, are infrequently
associated with this syndrome.19 In the present study, d4Tth in 125 HIV-infected patients with hyperlactatemia
OR 95% CI
20.372 2.610—159.001
9.090 1.575—52.632
0.999 0.996—1.002
0.660 0.121—3.605
1.006 0.931—1.088
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lactatemia. Thus, the contribution of other NRTIs to the
development of hyperlactatemia is relatively difficult to
evaluate because the majority of patients receive d4T due
to the accessibility and affordability of this NRTI in our
country. In addition, d4T is a recommended companion drug
in constructing the backbone of treatment according to the
current Thai national guidelines and World Health Organiza-
tion guidelines.20
In our study, patients with a high serum lactate level were
found to be at a higher risk ofmortality. A high level of lactate
is established to be correlated with a poor prognosis.4 Our
results correspond to the findings of a previous study that
showed a lactate level range of 5—10 mmol/l to be associated
with a mortality rate of 7% and a lactate level range of 10—
15 mmol/l to be associated with a mortality rate of >30%.4
Several studies have shown that themortality rate of patients
with a lactate level above 10 mmol/l is approximately
80%.4,6,21 Of note, total duration of drug exposure and female
gender had previously been established as risk factors for
mitochondrial toxicity.22 However, these factors were not
found to be significant risk factors for death in the patients
with symptomatic hyperlactatemia. A better understanding
of the clinical and pathophysiological correlations is needed.
Although full supportive treatment was given, the mor-
tality rate was still high during the first few days after
diagnosis. This may be explained by a failure or overwhelming
of the homeostatic regulation of blood lactate levels.19 This
results in decompensated hyperlactatemia or lactic acidosis
progressing rapidly among these patients.
Three significant factors including serum bicarbonate,
anion gap, and ALT level were not examined in the binary
logistic regression. The reason for this is that the results of
correlation analyses show that there is a correlation between
serum bicarbonate and lactate level (rs = 0.697, p < 0.001),
anion gap and lactate level (rs = 0.831, p < 0.001), and ALT
level and gender (rs = 0.207, p = 0.020).
In the resource-limited setting, d4T is still a preferred
companion NRTI drug, particularly because of its availability
in fixed-dose combinations for patients in developing coun-
tries. While ARTsignificantly decreases mortality in this area,
there is a substantial proportion of HIV-infected patients who
have experienced problems or who have died after the
initiation of ART due to this metabolic complication.23 This
makes it essential that all attending physicians, healthcare
providers, and patients in these community-based areas are
trained to recognize this condition early. Furthermore, the
role of d4T as a preferred companion NRTI drug should be
reconsidered in the upcoming revised treatment guidelines
for resource-limited settings including Thailand. NRTIs with
less toxicity should be considered. As mentioned, abacavir
and tenofovir have a very low affinity for mitochondrial DNA
polymerase gamma; these two drugs may be better choices.
However, abacavir is still difficult to access due to its high
cost in our country. Fortunately, tenofovir at US$1 per tablet
has recently been made available in Thailand and other Asian
countries (since December 2006). Thus, substitution of d4T
with tenofovir may be a favorable treatment strategy.
There are some limitations in the present study. First, it is
in the nature of retrospective studies that details of patient
clinical conditions may not be controlled and may be under-
estimated, such as a physical activity before phlebotomy andserology of hepatitis B and hepatitis C viruses. However, we
have the practice protocol to perform this laboratory test,
including 15 minutes of rest prior to phlebotomy and not
using tourniquets or fist clenching. Second, determination of
arterial pH was not performed routinely in our symptomatic
hyperlactatemic patients due to limited resources. Lastly,
approximately half of the patients were not confirmed as
cases by the second consecutive elevated lactate levels.
However, there were no differences in characteristics
between the two groups.
In conclusion, the mortality rate of symptomatic hyper-
lactatemia among HIV-infected patients receiving ART is
markedly high in our setting. The patients who had a low
body weight and a high serum lactate level were found to be
at higher risk of mortality. A high index of clinical suspicion is
the key to early diagnosis. Studies regarding future inter-
ventions should be conducted to minimize the mortality rate
in these patients.
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